Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Tourette Syndrome Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Tourette Syndrome Overview | 8 | 1 |
| Tourette Syndrome Therapeutics under Development by Companies | 9 | 1 |
| Tourette Syndrome Pipeline Products Glance | 10 | 3 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Unknown Stage Products | 12 | 1 |
| Tourette Syndrome Products under Development by Companies | 13 | 1 |
| Tourette Syndrome Companies Involved in Therapeutics Development | 14 | 7 |
| Catalyst Pharmaceuticals, Inc. | 14 | 1 |
| Neurocrine Biosciences, Inc. | 15 | 1 |
| Psyadon Pharmaceuticals, Inc. | 16 | 1 |
| Reviva Pharmaceuticals Inc. | 17 | 1 |
| Synchroneuron Inc. | 18 | 1 |
| Teva Pharmaceutical Industries Ltd. | 19 | 1 |
| Therapix Biosciences Ltd | 20 | 1 |
| Tourette Syndrome Therapeutics Assessment | 21 | 9 |
| Assessment by Monotherapy Products | 21 | 1 |
| Assessment by Combination Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 1 |
| Drug Profiles | 30 | 28 |
| (amfetamine + guanfacine hydrochloride) Drug Profile | 30 | 1 |
| acamprosate calcium SR Drug Profile | 31 | 2 |
| CPP-115 Drug Profile | 33 | 4 |
| deutetrabenazine ER Drug Profile | 37 | 5 |
| dronabinol + palmidrol Drug Profile | 42 | 1 |
| ecopipam hydrochloride Drug Profile | 43 | 3 |
| RP-5063 Drug Profile | 46 | 2 |
| valbenazine tosylate Drug Profile | 48 | 5 |
| vigabatrin Drug Profile | 53 | 5 |
| Tourette Syndrome Dormant Projects | 58 | 1 |
| Tourette Syndrome Discontinued Products | 59 | 1 |
| Tourette Syndrome Product Development Milestones | 60 | 10 |
| Featured News &Press Releases | 60 | 1 |
| Jun 15, 2016: Therapix Biosciences Filed an Application with the FDA to Approve an Orphan Designation for the Drug Developed Based on the Entourage Technology for Treating Tourettes Syndrome | 60 | 1 |
| Feb 03, 2016: Psyadon Announces Positive Independent Review of Phase 2b Study of Ecopipam for the Treatment of Tourette Syndrome in Children | 60 | 1 |
| Feb 02, 2016: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome | 61 | 1 |
| Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115 | 62 | 1 |
| Dec 16, 2015: Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome | 62 | 1 |
| Oct 20, 2015: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome | 63 | 1 |
| Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population | 64 | 1 |
| Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115 | 64 | 1 |
| Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study | 65 | 1 |
| May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette Syndrome in Children Ages 7-17 | 65 | 1 |
| Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome | 66 | 1 |
| Feb 09, 2012: Catalyst Files Provisional Patent Application For GABA Aminotransferase Inhibitor CPP-115 In Treatment Of Tourette Syndrome | 67 | 1 |
| Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854 | 68 | 1 |
| May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment | 68 | 1 |
| Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial | 69 | 1 |
| Appendix | 70 | 2 |
| Methodology | 70 | 1 |
| Coverage | 70 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Expert Panel Validation | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 71 | 1 |